TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06296134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perineal massage
Description: women affected by LAM co-activation allocated to the intervention perineal massage are asked to perform the perineal massage once daily from 34 gestational weeks until delivery. Women are trained to correctly perform the perineal massage at 30 gestaitonal weeks.
Study: NCT06548828

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NNS Restriction Intervention
Description: Discuss current scientific literature surrounding NNS consumption, obesity, and chronic disease and the emerging evidence that consumption in pregnancy/lactation may have unfavorable effects on infants' adiposity and health.~Provide detailed handouts, which will include a list of specific foods and beverages containing NNS to avoid during the study and summarize current scientific evidence on the metabolic and health effects of NNS.~Emphasize that sugar is not the best alternative to NNS, and that the participant should drink still water, sparkling water, flavored waters with no added sweeteners, or unsweetened tea instead.~Bi-weekly shipments of unsweetened beverages of participant's choice to replace usual consumption of NNS containing beverages.~Automated text messages will also be sent to mothers once per week with reminders that they should avoid NNS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NNS Restriction Intervention
Description: Discuss current scientific literature surrounding NNS consumption, obesity, and chronic disease and the emerging evidence that consumption in pregnancy/lactation may have unfavorable effects on infants' adiposity and health.~Provide detailed handouts, which will include a list of specific foods and beverages containing NNS to avoid during the study and summarize current scientific evidence on the metabolic and health effects of NNS.~Emphasize that sugar is not the best alternative to NNS, and that the participant should drink still water, sparkling water, flavored waters with no added sweeteners, or unsweetened tea instead.~Bi-weekly shipments of unsweetened beverages of participant's choice to replace usual consumption of NNS containing beverages.~Automated text messages will also be sent to mothers once per week with reminders that they should avoid NNS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Counsel about best practices for home safety and babyproofing.~Provide a detailed booklet to take home, which will provide information about home safety and baby proofing.~Educate about common causes of accidental infant and young child injuries or death.~Automated text messages will also be sent to mothers once per week with reminders about home safety, infant safety, and baby proofing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Counsel about best practices for home safety and babyproofing.~Provide a detailed booklet to take home, which will provide information about home safety and baby proofing.~Educate about common causes of accidental infant and young child injuries or death.~Automated text messages will also be sent to mothers once per week with reminders about home safety, infant safety, and baby proofing.
Study: NCT05571046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection of %0.9 isotonic sodium chloride, Paracetamol (500 mg, 2 times a day)
Study: NCT05737134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MA_PESAN MOBILE APPLICATION
Description: The intervention group was given a mobile application consisting of video, and educational material that information was provided regarding the prevention of child sexual abuse.
Study: NCT05452096

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program and ergonomic schedulling
Description: The duration: six months. The explicit choice for a multimodal intervention to be tested as a whole is in line with the assertion of other experts that workplace interventions using a single approach will not be effective.~Multimodal intervention~1. Implementing healthy scheduling. This will imply fast forward-rotating shift schedules, being adapted to chronotype, allowing for adequate resting times between shifts and series of shifts, allowing for napping at work, in particular during the first two days of an early shift.~2. Education program for drivers: psychoeducation on the sleep-wake cycle chronotypes, based on the cognitive-behavioral treatment of insomnia (CBT-i), information on the impact of light on wakefulness and sleep, information on napping and creating awareness on daytime sleepiness, tools for stress reduction, physical exercise, information on healthy eating in the context of shiftwork The education program will consist of a one-day, 8-hour session.
Study: NCT05087160

Intervention type: OTHER
Intervention: mitigation measures against COVID 19
Description: no intervention

Intervention type: OTHER
Intervention: mitigation measures against COVID 19
Description: no intervention
Study: NCT06196983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic aerobic exercises
Description: The experimental group's pattern of functional movements includes both right and left foot movements. To improve muscle strength and the capacity to maintain balance, exercises including running in place, side steps, walking while eating, and turning in place can also be used. The rhythmic aerobic group linked their motions to the rhythmic auditory stimuli in order to perform in a rhythmic manner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group, strength and balance exercises
Description: The control group engaged in strength and balance exercises where they stood with weight on one leg and raised the other leg to the side or back. In a tandem stance, place your foot heel directly in front of your toe. Get out of a chair, then take a seat without using your hands.
Study: NCT05431101

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Release
Description: Transection of flexor retinaculum for patients who have carpal tunnel syndrome

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Release
Description: Transection of flexor retinaculum for patients who have carpal tunnel syndrome
Study: NCT06181201

Intervention type: PROCEDURE
Intervention: Stool collection
Description: Stool collection is done with the Coll-off device (Zymo research, reference R1101-2-5) provided to the patient before and after the induction treatment and after the reference chemo-radiotherapy treatment (Cap50, Capecitabine). Collection must be carried out by the patient at home (collection using the Coll-off device and then transfer to a coproculture jar provided). The fresh sample is then picked up the same day by an approved transporter mandated by the promoter and will be stored at -20°C until the start of the analyses
Study: NCT04919525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrainPain
Description: Participants will use gamified sensory perceptual training technology once daily for 28 days. This will involve participants completing a 15 minute sensory training session using the provided technology and viewing a 5 minute web based pain management lesson; additionally, participants will receive daily text messages. The device used in this study has two components. The first is a video game that can be downloaded onto any smartphone device. The second component is two vibrational devices that can be attached to the arms, legs, upper back, and lower back.
Study: NCT05136365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiongdan Wan
Description: Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.
Study: NCT05777720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtration Fan
Description: Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe-home pamphlet
Description: The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid-week phone call
Description: On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
Study: NCT05360082

Intervention type: OTHER
Intervention: [11C]UCB-J
Description: 11C-labeled SV2A binding PET radioligand

Intervention type: OTHER
Intervention: [11C]UCB-J
Description: 11C-labeled SV2A binding PET radioligand

Intervention type: OTHER
Intervention: [11C]UCB-J
Description: 11C-labeled SV2A binding PET radioligand

Intervention type: OTHER
Intervention: [18F]SynVest-1
Description: 18F-labeled SV2A binding PET radioligand

Intervention type: OTHER
Intervention: [18F]SynVest-1
Description: 18F-labeled SV2A binding PET radioligand

Intervention type: OTHER
Intervention: [18F]SynVest-1
Description: 18F-labeled SV2A binding PET radioligand
Study: NCT04640961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Single injection into the shoulder joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
Study: NCT05716087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocbrutinib
Description: Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
Study: NCT04722341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE)
Description: 8-hour daily eating period, starting 1-3 hours after waking up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: More than equal to a 12-hour daily eating period
Study: NCT05228730

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tozinameran - Standard dose
Description: Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A standard dose will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozinameran - fractional dose
Description: Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Elasomeran - standard dose
Description: Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elasomeran - fractional dose
Description: Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study.
Study: NCT06120166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
Study: NCT05679466

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: randomized, double-blinded, placebo-controlled
Description: Approximately 3300 participants will be enrolled, including an immunogenic subgroup of approximately 240. Approximately 10% to 15% of all subjects will be 60 years of age and older. Enrolled subjects will be stratified by age (18-59 years, 60 years and older), number of previous doses of COVID-19 vaccine (2 or 3 doses), and interval from the last previous dose (180-365 days, 366-540 days). Participants will be randomized in a 1:1 ratio to receive 1 dose of the ReCOV or placebo on Day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: randomized, double-blinded, placebo-controlled
Description: Approximately 3300 participants will be enrolled, including an immunogenic subgroup of approximately 240. Approximately 10% to 15% of all subjects will be 60 years of age and older. Enrolled subjects will be stratified by age (18-59 years, 60 years and older), number of previous doses of COVID-19 vaccine (2 or 3 doses), and interval from the last previous dose (180-365 days, 366-540 days). Participants will be randomized in a 1:1 ratio to receive 1 dose of the ReCOV or placebo on Day 0.
Study: NCT06638671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
Study: NCT06267157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality training
Description: Group that will receive breastfeeding training with virtual glasses, in the metaverse universe.

Intervention type: OTHER
Group type: OTHER
Intervention: theoretical breastfeeding training
Description: Classic 2-hour theoretical breastfeeding training with ppt
Study: NCT04808986

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serological test for the detection of IgG anti-SARS-CoV-2
Description: Self-sampling dried-blood spot (DBS) kits will be send to each participant including material (a DBS card, lancets, pad), detailed printed instructionson how to perform thetest, and a self-addressed stamped padded envelope to be returned with the card to the centralized biobank (CEPH Biobank, Paris, France). Tubes will be sent sent to the virology laboratory (Unité des virus Émergents, Marseille, France) for serological analysis.
Study: NCT05821530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFIT
Description: At least 1 hour daily for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: At least 1 hour daily for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Users will continue to use the digital MSK program as needed
Study: NCT05682079

Intervention type: OTHER
Intervention: TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity
Description: The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device.

Intervention type: OTHER
Intervention: TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity
Description: The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device.
Study: NCT05903872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy massage
Description: aromatherapy massage was applied using essential oils

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: back massage
Description: back massage was applied using only almond oil
Study: NCT05545033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 5 to 15 minutes of virtual reality exposure
Study: NCT04822168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySafeRx™
Description: The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care through office-based opioid treatment with B/N dosing, on-site counseling and regular urine toxicology screening
Study: NCT04640298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
Study: NCT05501678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25mg (and up to 50mg) Diphenhydramine given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25mg (and up to 50mg) Diphenhydramine given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo given orally
Study: NCT04795843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and patient education
Description: Over a period of 6-months, patients will be offered eight one-to-one supervised training sessions. In these sessions, patients will be instructed in a home-based exercise programme and given patient education. The programme includes four exercises covering strength and stability training. The exercises will be performed in sets of three with a minimum of 5 repetitions, and patients will be instructed to perform a minimum of three training sessions each week. Each of the exercises can be progressed through three levels of difficulty, allowing for individualised treatment with regard to exercise quality and perceived exertion according to the Borg CR10 scale. Exercises will be performed on a perceived exertion level from somewhat hard (level 5) to very hard (level 7). Patient education includes pain management, a focus on exercise adherence and progression, and advice on physical activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will follow usual care, including an individual consultation on self-management of hip symptoms and general advice on exercise and physical activity.
Study: NCT06528964

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry and immunofluorescence
Description: Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated a-synuclein, amyloid-b, p-TAU and TDP-43.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry and immunofluorescence
Description: Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated a-synuclein, amyloid-b, p-TAU and TDP-43.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry and immunofluorescence
Description: Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated a-synuclein, amyloid-b, p-TAU and TDP-43.
Study: NCT06070194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating (TRE)
Description: Subjects randomized to this arm will be asked to follow an 8h eating duration/day for 4 weeks. Participants will be asked to continue habitual sleep patterns.
Study: NCT05789797

Intervention type: DRUG
Intervention: Remaxol
Description: Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
Study: NCT05012982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirBand
Description: The AirBands will be placed at each of the two training sessions and inflated while an ultrasound probe is placed over the femoral artery. The cuff will be inflated until the artery reaches 60% occlusion. The force will be applied using a wireless Bluetooth signal; participants will not be asked to adjust the device. Participants will be observed by a certified Personal Therapist throughout the training session in order to determine compliance and ensure safety as is standard protocol for a physical therapy session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirBand
Description: The AirBands will be placed at each of the two training sessions and inflated while an ultrasound probe is placed over the femoral artery. The cuff will be inflated until the artery reaches 60% occlusion. The force will be applied using a wireless Bluetooth signal; participants will not be asked to adjust the device. Participants will be observed by a certified Personal Therapist throughout the training session in order to determine compliance and ensure safety as is standard protocol for a physical therapy session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uninflated AirBand
Description: Uninflated AirBand will be used as the control intervention during the session in which BFR is not performed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uninflated AirBand
Description: Uninflated AirBand will be used as the control intervention during the session in which BFR is not performed